End-of-day quote
Korea S.E.
03:30:00 24/06/2024 am IST
|
5-day change
|
1st Jan Change
|
1,995
KRW
|
-16.53%
|
|
-22.67%
|
-55.37%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,62,935
|
3,94,737
|
4,77,802
|
1,14,342
|
60,805
|
Enterprise Value (EV)
1 |
2,36,542
|
3,82,720
|
4,73,510
|
1,07,584
|
57,387
|
P/E ratio
|
-103
x
|
-95.1
x
|
-36.5
x
|
-5
x
|
-4.15
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
52,55,81,679
x
|
23,82,11,476
x
|
-
|
EV / Revenue
|
-
|
-
|
52,08,60,841
x
|
22,41,34,002
x
|
-
|
EV / EBITDA
|
-69.1
x
|
-79.8
x
|
-44.2
x
|
-8.74
x
|
-6.02
x
|
EV / FCF
|
-40.1
x
|
-25.8
x
|
-57.4
x
|
-30.9
x
|
-2.89
x
|
FCF Yield
|
-2.49%
|
-3.88%
|
-1.74%
|
-3.24%
|
-34.6%
|
Price to Book
|
5.12
x
|
8.35
x
|
12.3
x
|
5.1
x
|
1.5
x
|
Nbr of stocks (in thousands)
|
9,579
|
9,699
|
9,731
|
9,731
|
13,603
|
Reference price
2 |
27,450
|
40,700
|
49,100
|
11,750
|
4,470
|
Announcement Date
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
909.1
|
480
|
-
|
EBITDA
1 |
-2,298
|
-3,421
|
-4,795
|
-10,723
|
-12,311
|
-9,534
|
EBIT
1 |
-2,375
|
-3,531
|
-5,287
|
-13,011
|
-14,911
|
-12,198
|
Operating Margin
|
-
|
-
|
-
|
-1,431.2%
|
-3,106.53%
|
-
|
Earnings before Tax (EBT)
1 |
-11,286
|
-2,494
|
-4,126
|
-13,071
|
-22,865
|
-11,611
|
Net income
1 |
-11,286
|
-2,494
|
-4,126
|
-13,071
|
-22,865
|
-11,611
|
Net margin
|
-
|
-
|
-
|
-1,437.76%
|
-4,763.45%
|
-
|
EPS
2 |
-1,424
|
-265.7
|
-427.9
|
-1,346
|
-2,350
|
-1,078
|
Free Cash Flow
1 |
-11,116
|
-5,893
|
-14,832
|
-8,255
|
-3,485
|
-19,854
|
FCF margin
|
-
|
-
|
-
|
-908.07%
|
-726.13%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/03/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
7,885
|
26,394
|
12,017
|
4,292
|
6,757
|
3,418
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-11,116
|
-5,893
|
-14,832
|
-8,255
|
-3,485
|
-19,854
|
ROE (net income / shareholders' equity)
|
-283%
|
-7.69%
|
-8.37%
|
-30.4%
|
-74.7%
|
-36.9%
|
ROA (Net income/ Total Assets)
|
-15.5%
|
-6.61%
|
-6.48%
|
-15.1%
|
-17.9%
|
-13.9%
|
Assets
1 |
72,923
|
37,703
|
63,634
|
86,520
|
1,27,716
|
83,601
|
Book Value Per Share
2 |
1,574
|
5,359
|
4,877
|
3,983
|
2,306
|
2,977
|
Cash Flow per Share
2 |
103.0
|
175.0
|
358.0
|
535.0
|
848.0
|
984.0
|
Capex
1 |
5,817
|
4,284
|
11,715
|
3,112
|
1,203
|
6,922
|
Capex / Sales
|
-
|
-
|
-
|
342.29%
|
250.61%
|
-
|
Announcement Date
|
01/03/19
|
29/02/20
|
01/03/21
|
01/03/22
|
01/03/23
|
29/02/24
|
|
1st Jan change
|
Capi.
|
---|
| -55.37% | 2.12Cr | | +16.45% | 12TCr | | +21.96% | 12TCr | | +22.15% | 2.7TCr | | -20.05% | 2.04TCr | | -17.01% | 1.64TCr | | -16.28% | 1.59TCr | | -44.35% | 1.56TCr | | +63.91% | 1.49TCr | | +2.52% | 1.36TCr |
Bio Therapeutic Drugs
|